Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03091764 · ClinicalTrials.gov registry record

Evaluation of a Patient-Reported Symptom Index for NMIBC

A clinical trial, sponsored by University of Sydney.

Completed
Registry status
498
Enrollment target

NCT03091764 is a clinical trial that has completed, run by University of Sydney. The registered enrollment target is 498 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03091764 has completed, sponsored by University of Sydney.

COMPLETED
Registry status
498 participants
Enrollment target

Study Summary

This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.

Trial Details

FieldValue
Enrollment Target 498 participants
Start Date 2016-07-01
Est. Completion 2021-08-30

Sponsor

University of Sydney

9 total trials

What the Registry Record Tells You About NCT03091764

The ClinicalTrials.gov registry entry for NCT03091764 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Sydney, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT03091764 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03091764 about?

NCT03091764 is a clinical study titled "Evaluation of a Patient-Reported Symptom Index for NMIBC". This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; he...

What is the current status of trial NCT03091764?

This trial is currently completed. The enrollment target is 498 participants. The study started on 2016-07-01. Estimated completion is 2021-08-30.

Who is sponsoring clinical trial NCT03091764?

This trial is sponsored by University of Sydney, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.